Hot Keyworkds: battery
Your Location:www.global.chinaomp.com » Products » Chemicals » Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

Publish Time: 2017-03-27

Region: »

Industry: Chemicals»Organic Intermediate

Keywords:


hubeiycltd

Contact:tmac
Member type:Corporate Member
Reputation:0
Authentication Type:

Product Details

Product Name Bivalirudin Trifluoroacetate


Sequence D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH


Cas No. 128270-60-0


Molecular Formula C98H138N24O33


Molecular Weight 2180.33


Purity (HPLC) 98.0%min.


Appearance? White Powder


Single Impurity (HPLC)? 1.0%max


Amino Acid Composition? ±10% of theoretical


Peptide Content (N%) ≥80.0%


Water Content (Karl Fischer)? ≤8.0%


TrifluoroAcetate Content(HPIC) ≤12.0%


MS (ESI) Consistent


Mass Balance? 95.0~105.0%



2. Description:


Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).


Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.


Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.



3. Application:


Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).


Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).


Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.


Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Only registered member can view the contact

If you already a member, please

If you are not a member, please

Quote of the product-related